Efavirenz,Tenofovir and Emtricitabine Combined with First-Line Tuberculosis Treatment in Tuberculosis–Hiv-Coinfected Tanzanian Patients: A Pharmacokinetic and Safety Study

Abstract

Background

To evaluate the effect of rifampicin-based tuberculosis (TB) treatment on the pharmacokinetics of efavirenz/tenofovir/emtricitabine in a fixed-dose combination tablet, and vice versa, in Tanzanian TB–HIV-coinfected patients.

Methods

This was a Phase II open-label multiple dose pharmacokinetic and safety study. This study was conducted in TB–HIV-coinfected Tanzanian patients who started TB treatment (rifampicin/isoniazid/pyrazinamide/ethambutol) at week 1 to week 8 and continued with rifampicin and isoniazid for another 16 weeks. Antiretroviral treatment (ART) of efavirenz/tenofovir/emtricitabine in a fixed-dose combination tablet was started at week 4 after initiation of TB treatment. A 24-h pharmacokinetic sampling curve was recorded at week 8 (with TB treatment) and week 28 (ART alone). For TB drugs, blood samples at 2 and 5 h post-dose were taken at week 3 (TB treatment alone) and week 8 (with ART).

Results

A total of 25 patients (56% male) completed the study; 21 had evaluable pharmacokinetic profiles. The area under the concentration–time curve 0–24 h post-dose of efavirenz, tenofovir and emtricitabine were slightly higher when these drugs were coadministered with TB drugs; geometric mean ratios (90% CI) were 1.08 (0.90, 1.30), 1.13 (0.93, 1.38) and 1.05 (0.85, 1.29), respectively. For TB drugs, equivalence was suggested for peak plasma concentrations when administered with and without efavirenz/tenofovir/emtricitabine. Adverse events were mostly mild and no serious adverse events or drug discontinuations were reported.

Conclusions

Coadministration of efavirenz, tenofovir and emtricitabine with a standard first-line TB treatment regimen did not significantly alter the pharmacokinetic parameters of these drugs and was tolerated well by Tanzanian TB patients who are coinfected with HIV.

References

World Health Organization. Global tuberculosis control: WHO report 2011. Geneva: World Health Organization 2011.

Corbett

E.L.

, Marston

, Churchyard

G.J.

, De Cock

K.M.

Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006; 367: 926–937.

Lawn

S.D.

, Churchyard

Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS 2009; 4: 325–333.

Manosuthi

, Kiertiburanakul

, Sungkanuparph

Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS 2006; 20: 131–132.

Niemi

, Backman

J.T.

, Fromm

M.F.

, Neuvonen

P.J.

, Kivisto

K.T.

Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42: 819–850.

Finch

C.K.

, Chrisman

C.R.

, Baciewicz

A.M.

, Self

T.H.

Rifampin and rifabutin drug interactions: an update. Arch Intern Med 2002; 162: 985–992.

Burman

W.J.

, Gallicano

, Peloquin

Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001; 40: 327–341.

World Health Organisation. Treatment of tuberculosis: guidelines. 4th Ed. Geneva: World Health Organisation 2010.

World Health Organisation. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 Revision. Geneva: World Health Organisation 2010.

10.

Kwara

, Tashima

K.T.

, Dumond

J.B.

Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers. Antimicrob Agents Chemother 2011; 55: 3527–3533.

11.

López-Cortés

L.F.

, Ruiz-Valderas

, Viciana

Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002; 41: 681–690.

12.

Friedland

, Khoo

, Jack

, Lalloo

Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 2006; 58: 1299–1302.

13.

Semvua

H.H.

, Kibiki

G.S.

AtriplaR/anti-TB combination in TB/ HIV patients. Drug in focus. BMC Res Notes 2011; 4: 511.

14.

Aarnoutse

R.E.

, Grintjes

K.J.

, Telgt

D.S.

The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin Pharmacol Ther 2002; 71: 57–67.

15.

Droste

J.A.H.

, Verweij-van Wissen

C.P.W.G.M.

, Kearney

B.P.

Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2005; 49: 680–684.

16.

la Porte

C.J.

, Colbers

E.P.

, Bertz

Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004; 48: 1553–1560.

17.

Ruslami

, Nijland

H.M.

, Alisjahbana

, Parwati

, van Crevel

, Aarnoutse

R.E.

Pharmacokinetics and tolerability of a higher rifampicin dose versus the standard dose in pulmonary tuberculois patients. Antimicrob Agents Chemother 2007; 51: 2546–2551.

18.

Williams

R.L.

, Chen

M.L.

, Hauck

W.W.

Equivalence approaches. Clin Pharmacol Ther 2002; 72: 229–237.

19.

Marzolini

, Telenti

, Decosterd

L.A.

, Greub

, Biollaz

, Buclin

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15: 71–75.

20.

Cohen

, Grant

, Dandara

Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 2009; 14: 687–695.

21.

Ngaimisi

, Mugusi

, Minzi

Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin Pharmacol Ther 2011; 90: 406–413.

22.

Orrell

, Cohen

, Conradie

Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?

Antivir Ther 2011; 16: 527–534.

23.

Ramachandran

, Hemanth Kumar

A.K.

, Rajasekaran

CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Antimicrob Agents Chemother 2009; 53: 863–868.

24.

Kwara

, Lartey

, Sagoe

K.W.

Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. J Clin Pharmacol 2008; 48: 1032–1040.

25.

Uttayamakul

, Likanonsakul

, Manosuthi

Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. AIDS Res Ther 2010; 7: 8.

26.

di Iulio

, Fayet

, Arab-Alameddine

In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 2009; 19: 300–309.

27.

Haas

D.W.

, Gebretsadik

, Mayo

Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. J Infect Dis 2009; 199: 872–880.

28.

Powers

, Ward

, Gompels

CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation. HIV Med 2009; 10: 520–523.

29.

King

, Aberg

J.A.

Clinical impact of patient population differences and genomic variation in efavirenz therapy. AIDS 2008; 22: 1709–1717.

30.

Nyakutira

, Roshammar

, Chigutsa

High prevalence of the CYP2B6 516G–>T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/ AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 2008; 64: 357–365.

31.

Blumberg

H.M.

, Burman

W.J.

, Chaisson

R.E.

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603–662.

32.

Klein

, Lang

, Saussele

Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 2005; 15: 861–873.

33.

Friedland

, Churchyard

G.J.

, Nardell

Tuberculosis and HIV coinfection: current state of knowledge and research priorities. J Infect Dis 2007; 196 Suppl 1: S1–S3.

34.

Abdool Karim

S.S.

, Naidoo

, Grobler

Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362: 697–706.

35.

Lee

B.L.

, Wong

, Benowitz

N.L.

, Sullam

P.M.

Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 1993; 53: 529–535.

36.

Barditch-Crovo

, Deeks

S.G.

, Collier

Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001; 45: 2733–2739.

37.

Kwara

, Lartey

, Sagoe

K.W.

, Court

M.H.

Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. AIDS 2011; 25: 388–390.

38.

Peloquin

C.A.

Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62: 2169–2183.

39.

Lin

M.Y.

, Lin

S.J.

, Chan

L.C.

, Lu

Y.C.

Impact of food and antacids on the pharmacokinetics of anti-tuberculosis drugs: systematic review and meta-analysis. Int J Tuberc Lung Dis 2010; 14: 806–818.